RAPT Therapeutics (RAPT) Accumulated Expenses: 2020-2024
Historic Accumulated Expenses for Therapeutics (RAPT) over the last 5 years, with Sep 2024 value amounting to $6.4 million.
- Therapeutics' Accumulated Expenses fell 54.65% to $6.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $6.4 million, marking a year-over-year decrease of 54.65%. This contributed to the annual value of $14.1 million for FY2023, which is 62.93% up from last year.
- Latest data reveals that Therapeutics reported Accumulated Expenses of $6.4 million as of Q3 2024, which was down 32.56% from $9.5 million recorded in Q2 2024.
- Therapeutics' 5-year Accumulated Expenses high stood at $14.1 million for Q3 2023, and its period low was $3.8 million during Q1 2020.
- Over the past 3 years, Therapeutics' median Accumulated Expenses value was $9.5 million (recorded in 2024), while the average stood at $9.9 million.
- Per our database at Business Quant, Therapeutics' Accumulated Expenses spiked by 82.33% in 2022 and then crashed by 54.65% in 2024.
- Quarterly analysis of 5 years shows Therapeutics' Accumulated Expenses stood at $4.9 million in 2020, then grew by 28.19% to $6.3 million in 2021, then surged by 36.83% to $8.7 million in 2022, then surged by 62.93% to $14.1 million in 2023, then slumped by 54.65% to $6.4 million in 2024.
- Its last three reported values are $6.4 million in Q3 2024, $9.5 million for Q2 2024, and $11.8 million during Q1 2024.